Nurix Therapeutics' stock has surged, with reports of a collaboration with Roche on a blood cancer drug that could tap into a large market. The terms of the agreement are unclear, with various figures reported, including $2 billion, $2.3 billion, and $700 million. The partnership appears to involve a license deal for a Nurix Therapeutics drug, but details of the agreement are not consistent across reports.